InsiderClue
Stocks · Health care · Pharmaceutical Preparations

60 DEGREES PHARMACEUTICALS, INC.

SXTP Clue Score65
United States Fiscal year ends December CIK 0001946563
$0.97 -0.73% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.97 +16.45% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Jul 2023. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2022Revenue0.2Operating income−1.8Net income−6.2EPS, diluted−2.61Fiscal year 2023Revenue0.3 +13.6%Operating income−5.2Net income−3.8EPS, diluted−59.18Fiscal year 2024Revenue0.6 +139.6%Operating income−9.7Net income−7.9EPS, diluted−74.17Fiscal year 2025Revenue1.0 +65.5%Operating income−7.8Net income−7.4EPS, diluted−11.73
FY2022FY2023FY2024FY2025
Revenue 0.2 0.3 0.6 1.0
Growth +13.6% +139.6% +65.5%
Operating income −1.8 −5.2 −9.7 −7.8
Net income −6.2 −3.8 −7.9 −7.4
Growth
EPS, diluted −2.61 −59.18 −74.17 −11.73

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2022Gross margin−93.7%Operating margin−784.2%Net margin−2,769.5%Fiscal year 2023Gross margin−87.1%Operating margin−2,032.8%Net margin−1,485.1%Free cash flow margin−1,814.3%Fiscal year 2024Gross margin36.7%Operating margin−1,599.0%Net margin−1,308.0%Free cash flow margin−946.7%Fiscal year 2025Gross margin22.3%Operating margin−771.6%Net margin−732.5%Free cash flow margin−695.1%
FY2022FY2023FY2024FY2025
Gross margin −93.7% −87.1% 36.7% 22.3%
Operating margin −784.2% −2,032.8% −1,599.0% −771.6%
Net margin −2,769.5% −1,485.1% −1,308.0% −732.5%
Free cash flow margin n/a −1,814.3% −946.7% −695.1%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2022Operating cash flow−1.0Fiscal year 2023Operating cash flow−4.5Capital expenditure−0.1Free cash flow−4.6Fiscal year 2024Operating cash flow−5.6Capital expenditure−0.1Free cash flow−5.8Fiscal year 2025Operating cash flow−6.8Capital expenditure−0.1Free cash flow−7.0
FY2022FY2023FY2024FY2025
Operating cash flow −1.0 −4.5 −5.6 −6.8
Capital expenditure n/a −0.1 −0.1 −0.1
Free cash flow n/a −4.6 −5.8 −7.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2022Cash0.3Total debt16.9Net cash (debt)−16.6Shareholders’ equity−23.6Fiscal year 2023Cash2.1Total debt0.2Net cash (debt)2.0Shareholders’ equity4.9Debt to equity0.03Fiscal year 2024Cash1.7Total debt0.2Net cash (debt)1.5Shareholders’ equity4.0Debt to equity0.04Fiscal year 2025Cash1.5Total debt0.2Net cash (debt)1.4Shareholders’ equity3.5Debt to equity0.04
FY2022FY2023FY2024FY2025
Cash 0.3 2.1 1.7 1.5
Total debt 16.9 0.2 0.2 0.2
Net cash (debt) −16.6 2.0 1.5 1.4
Shareholders’ equity −23.6 4.9 4.0 3.5
Debt to equity n/a 0.03 0.04 0.04

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−93.7% −87.1% 36.7% 22.3%
−784.2% −2,032.8% −1,599.0% −771.6%
−2,767.5% −1,503.9% −1,309.4% −732.8%
−2,769.5% −1,485.1% −1,308.0% −732.5%
n/a −1,814.3% −946.7% −695.1%
Spending
235.5% 272.8% 820.7% 209.5%
584.1% 1,672.8% 827.1% 624.6%
n/a 22.7% 17.1% 13.9%
Returns
n/a −77.3% −196.9% −212.7%
−476.5% −48.4% −138.0% −137.3%
Balance and payout
n/a 0.03 0.04 0.04
1,961.6% 38.4% 31.3% 37.0%